SynthesisBlood advances2020
Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses.
Synthesis in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- Drugs to Prevent and Treat Venous Thromboembolic Disease During Pregnancy.Clinics in perinatology · 2026Review
- Nonheparin-bonded stent relining in a case of subacute in-stent thrombosis secondary to heparin-induced thrombocytopenia.Journal of vascular surgery cases and innovative techniques · 2026Article
- Anticoagulants beyond coagulation: a narrative review of cardiovascular effects.Cardiovascular research · 2026Review
- Case Report: HIT-related valve thrombosis in an LVAD patient.Frontiers in cardiovascular medicine · 2026Article
- Fondaparinux versus argatroban for the management of suspected or confirmed heparin-induced thrombocytopenia: a propensity score-matched cohort study.Frontiers in medicine · 2026Article
- Evaluation of an IgG anti-PF4/H chemiluminescent immunoassay in the diagnosis of heparin-induced thrombocytopenia.Blood vessels, thrombosis & hemostasis · 2025Article
- Article
- Heparin-Induced Thrombocytopenia and Thrombosis in Patients With or Without a Thrombophilia Background: A Systematic Review Involved 602 Cases.International journal of vascular medicine · 2025Review
- Low-molecular-weight heparin-induced thrombocytopenia with multisite embolism: successful management with argatroban and dabigatran - a case report and literature review.Frontiers in pharmacology · 2025Article
- Opioid analgesics for chronic noncancer pain in patients prescribed opioid agonist therapy or with opioid use disorder: A systematic review.Canadian journal of pain = Revue canadienne de la douleur · 2025Review
- Acquired platelet disorders.Frontiers in medicine · 2025Review
- Approaches to management of HIT in complex scenarios, including cardiac surgery.Hematology. American Society of Hematology. Education Program · 2024Review
- Article
- Outcomes After Decompressive Surgery for Severe Cerebral Venous Sinus Thrombosis Associated or Not Associated with Vaccine-Induced Immune Thrombosis with Thrombocytopenia: A Multicenter Cohort Study.Neurocritical care · 2024Article
- Association of medical comorbidities in obese subjects diagnosed with heparin-induced thrombocytopenia.SAGE open medicine · 2024Article
- Applications and future of aptamers that achieve rapid-onset anticoagulation.RNA (New York, N.Y.) · 2023Article
- Anticoagulation Therapy for Pregnancy-Associated Thrombosis: A Retrospective Observational Study.Annals of vascular diseases · 2022Article
- Early Utilization of Intravenous Immunoglobulin in Heparin-Induced Thrombocytopenia for Limb Salvaging Purposes.Cureus · 2022Article
- Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome.International journal of molecular sciences · 2021Review
- European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination.European stroke journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin-induced thrombocytopenia (HIT) is a prothrombotic adverse drug reaction occurring in <0.1% to 7% of patients receiving heparin products depending on the patient population and type of heparin. Management of HIT is highly dependent on a sequence of tests for which clinicians may or may not have the results when care decisions need to be made. We conducted systematic reviews of the effects of management strategies in persons with acute HIT, subacute HIT A or B, and remote HIT. We searched Medline, EMBASE, and the Cochrane Database through July 2019 for previously published systematic reviews and primary studies. Two investigators independently screened and extracted data and assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. We found primarily noncomparative studies and case series assessing effects of treatments, which led to low to very low certainty evidence. There may be little to no difference in the effects between nonheparin parenteral anticoagulants and direct oral anticoagulants in acute HIT. The benefits of therapeutic-intensity may be greater than prophylactic-intensity anticoagulation. Using inferior vena cava filters or platelet transfusion may result in greater harm than not using these approaches. Evidence for management in special situations, such as for patients undergoing cardiovascular interventions or renal replacement therapy, was also low to very low certainty. Additional research to evaluate nonheparin anticoagulants is urgently needed, and the development of novel treatments that reduce thrombosis without increasing hemorrhage should be a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.